OPEN END TURBO LONG - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 12:27:26 15/06/2024 am IST | ||
| 30.13 EUR | +1.79% |
|
| Current month | +11.97% | ||
| 1 month | +21.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 30.13 | +1.79% |
| 13/24/13 | 29.6 | +0.99% |
| 12/24/12 | 29.31 | -2.59% |
| 11/24/11 | 30.09 | +0.13% |
| 10/24/10 | 30.05 | -0.03% |
Delayed Quote Börse Stuttgart
Last update June 15, 2024 at 12:27 am IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MC1UYN |
| ISIN | DE000MC1UYN0 |
| Date issued | 22/05/2019 |
| Strike | 160.4 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 30.16 € |
|---|---|
| Lowest since issue | 3.72 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat
